This study will help researchers understand the mechanisms by which SGLT2 inhibitors and dual SGLT1/2 inhibitors affect DM-HFrEF and provide important information about the potential benefits of these inhibitors for DM patients with HF. This evidence concerns the gene SLC5A1 and diabetes mellitus.